Biologic basis of sequential and combination therapies for hormone-responsive breast cancer

Oncologist

Volumn 11, Issue 7, 2006, Pages 707-717

  Pietras, Richard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AKT kinase signaling; Aromatase inhibitors; Estrogen receptors; Fulvestrant; Growth factors; MAP kinase signaling pathway Genes, HER 2

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FORMESTANE; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RALOXIFENE; SORAFENIB; TAMOXIFEN; TAMOXIFEN CITRATE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG BINDING; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT FAILURE; TUMOR GROWTH; BREAST TUMOR; FORECASTING; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 33746639733     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-7-704     Document Type: Review

References (102)

1. Katzenellenbogen BS, Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin Oncol 2004;31(suppl 3):28-38.
2. Robertson JFR, Cannon PM, Nicholson RI et al. Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer. Int J Biol Markers 1996;11:29-35.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
4. Pritchard KI. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res 2003;9:460S-467S.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
6. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003;63:6523-6531.
7. Favoni RE, de Cupis A. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Trends Pharmacol Sci 1998;19:406-415.
8. Lønning PE, Lien EA. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Hematol 1995;21:158-193.
9. Petz LN, Ziegler YS, Loven MA et al. Estrogen receptor a and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 2002;143:4583-4591.
10. Kushner PJ, Agard DA, Greene GL et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000;74:311-317.
11. Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-831.
12. Green S, Walter P, Kumar V et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986;320:134-139.
13. Keaveney M, Klug J, Dawson MT et al. Evidence for a previously unidentified upstream exon in the human oestrogen receptor gene. J Mol Endocrinol 1991;6:111-115.
14. Piva R, Bianchi N, Aguiari GL et al. Sequencing of an RNA transcript of the human estrogen receptor gene: evidence for a new transcriptional event. J Steroid Biochem Mol Biol 1993;46:531-538.
15. Maruyama S, Fujimoto N, Asano K et al. Suppression by estrogen receptor beta of AP-1 mediated transactivation through estrogen receptor alpha. J Steroid Biochem Mol Biol 2001;78:177-184.
16. Tang Z, Treilleux I, Brown M. A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers. Mol Cell Biol 1997;17:1274-1280.
17. Daschner PJ, Ciolino HP, Plouzek CA et al. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 1999;53:229-240.
18. Watanabe T, Inoue S, Ogawa S et al. Agonistic effects of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 1997;236:140-145.
19. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 1995;49:241-257.
20. Badia E, Duchesne M-J, Semlali A et al. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 2000;60:4130-4138.
21. Herynk MH, Fuqua SAW. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869-898.
22. Fuqua SAW, Schiff R, Parra I et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003;63:2434-2439.
23. Hong SH, Nah HY, Lee YJ et al. Expression of estrogen receptor-α and -β, glucocorticoid receptor, and progesterone receptor genes in human embryonic stem cells and embryoid bodies. Mol Cells 2004;18:320-325.
24. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004;15:193-197.
25. Yamamoto Y, Wada O, Suzawa M et al. The tamoxifen-responsive estrogen receptor α Mutant D351Y shows reduced tamoxifen-dependent interaction with copressor complexes. J Biol Chem 2001;276:42684-42691.
26. Tonetti DA, Jordan VC. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J Steroid Biochem Mol Biol 1997;62:119-128.
27. Katzenellenbogen BS, Montano MM, Ekena K et al. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 1997;44:23-38.
28. Zhang Q-X, Borg A, Wolf DM et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997;57:1244-1249.
29. Howell A, Osborne CK, Morris C et al. ICI 182,780 (Faslodex™): development of a novel, "pure" antiestrogen. Cancer 2000;89:817-825.
30. Johnston SRD. Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs 1997;8:911-930.
31. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992;326:1756-1761.
32. Osborne CK, Schiff R, Arpino G et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 2005;14:458-465.
33. Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7517.
34. Cui X, Schiff R, Arpino G et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005;23:7721-7735.
35. Lake DE, Hudis C. Aromatase inhibitors in breast cancer: an update. Cancer Control 2002;9:490-498.
36. Carlson RW. Sequencing of endocrine therapies in breast cancer-integration of recent data. Breast Cancer Res Treat 2002;75(suppl 1):S27-S32; discussion S33-S35.
37. Dellapasqua S, Castiglione-Gertsch M. The choice of systemic adjuvant therapy in receptor-positive early breast cancer. Eur J Cancer 2005;41:357-364.
38. DeFriend DJ, Howell A, Nicholson RI et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994;54:408-414.
39. McClelland RA, Manning DL, Gee JMM et al. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat 1996;41:31-41.
40. Sommer A, Hoffmann J, Lichtner RB et al. Studies on the development of resistance to the pure antiestrogen Faslodex™ in three human breast cancer cell lines. Steroid Biochem Mol Biol 2003;85:33-47.
41. Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004;90(suppl 1):S15-S18.
42. Pietras RJ, Szego CM. Plasma membrane for steroid hormones in cell signaling and nuclear function. In: Melmed S, Conn PM, eds. Endocrinology: Basic and Clinical Principles, Second Edition. Totowa, NJ: Humana Press, 2005:67-84.
43. Freeman MR, Cinar B, Lu ML. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005;16:273-279.
44. Masamura S, Santner SJ, Heitjan DF et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-2925.
45. Santen RJ, Song RX, Zhang Z et al. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 2004;10:337S-345S.
46. Santen R, Jeng MH, Wang JP et al. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001;79:115-125.
47. Yue W, Santen RJ, Wang J-P et al. Aromatase within the breast. Endocr Relat Cancer 1999;6:157-164.
48. Berstein LM, Zheng H, Yue W et al. New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 2003;10:267-277.
49. Shim WS, Conaway M, Masamura S et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396-405.
50. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-1494.
51. Kinoshita Y, Chen S. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor α. Cancer Res 2003;63:3546-3555.
52. Bunone G, Briand P-A, Miksicek RJ et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-2183.
53. Marquez DC, Lee J, Lin T et al. Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 2001;16:73-81.
54. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
55. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 2003;9:361-373.
56. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-1622.
57. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005;19:1951-1959.
58. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999;237:1-30.
59. Hyder SM, Nawaz Z, Chiappetta C et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000;60:3183-3190.
60. Ruohola JK, Valve EM, Karkkainen MJ et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999;149:29-40.
61. Rydén L, Jirström K, Bendahl P-O et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005;23:4695-4704.
62. Lipton A, Ali SM, Leitzel K et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-1472.
63. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-1/neu oncogene. Science 1987;235:177-182.
64. Pietras RJ, Marquez DC, Chen H-W et al. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat 2003;82(suppl 1):12-13.
65. Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-2446.
66. Baum M, Buzdar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
67. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
68. Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
69. Viale G, Regan M, Dell'Orto P et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005;94(suppl 1):S13.
70. Buzdar AU, Baum M, Cuzick J. Letrozole or tamoxifen in early breast cancer. N Engl J Med 2006;354:1528.
71. Chlebowski RT. Letrozole or tamoxifen in early breast cancer. N Engl J Med 2006;354:1529.
72. Coates AS, Mouridsen H, Mauriac L et al. Letrozole or tamoxifen in early breast cancer. N Engl J Med 2006;354:1529.
73. Erban JK. Letrozole or tamoxifen in early breast cancer. N Engl J Med 2006;354:1529.
74. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
75. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-5147.
76. Jakesz R, Kaufmann M, Gnant M et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years of adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;88(suppl 1):S7.
77. Jonat W, Gnant M, Bocccardo F et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. Breast Cancer Res Treat 2005;94(suppl 1):S11.
78. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
79. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
80. Goss PE, Ingle JN, Palmer MJ et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. Breast Cancer Res Treat 2005;94(suppl 1):S10.
81. Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998;83:1142-1152.
82. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind, randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461.
83. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-1411.
84. Lønning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-2244.
85. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-2258.
86. Mourisden H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
87. Howell A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104:236-239.
88. Howell A, Robertson JFR, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-3403.
89. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-3395.
90. Robertson JFR, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-238.
91. Carlson RW, Henderson IC. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat 2003;80(suppl 1):S19-S26; discussion S27-S28.
92. Osipo C, Gajdos C, Cheng D et al. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol 2005;93:249-256.
93. Ingle JN, Suman VJ, Rowland KM et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24:1052-1056.
94. Perey L, Paridaens R, Nolé F et al. Fulvestrant (Faslodex®) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 2004;88(suppl 1):S236.
95. Lønning PE, Taylor PD, Anker G et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111-116.
96. Lewis JS, Meeke K, Osipo C et al. Intrinsic mechanism of estradiolinduced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97:1746-1759.
97. Song RX-D, Mor G, Naftolin F et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J Natl Cancer Inst 2001;93:1714-1723.
98. Yao K, Lee E-S, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:2028-2036.
99. Come SE, Borges VF. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer 2005;6(suppl 1):S15-S22.
100. Peethambaram PP, Ingle JN, Suman VJ et al. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer: an updated analysis. Breast Cancer Res Treat 1999;54:117-122.
101. Sahmoud T. Fulvestrant (Faslodex): current and future perspectives. Presented at the Lynn Sage Breast Cancer Symposium, Chicago, Illinois, October 28, 2004.
102. Johnston SRD, Martin L-A, Head J et al. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2005;95:173-181.